Engineered FVIII A1 Domain Mutations for Hemophilia Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A, such as replacement therapy, often fail due to the generation of inhibitors against injected factor VIII, and gene therapy using rAAV vectors faces challenges like inefficient secretion of FVIII and immune responses due to high viral vector doses, which can lead to adverse reactions.
Innovation Solution
Engineered human factor VIII polypeptides with specific amino acid substitutions in the A1 domain, combined with rAAV vectors for gene therapy, aim to enhance secretion and reduce the required viral vector dose by modifying the amino acid sequence to improve clotting activity and stability, thereby increasing the effectiveness of FVIII expression and reducing adverse immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If replacement therapy with factor VIII concentrates is used, then clotting activity is improved, but inhibitors are generated against the injected factor VIII
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of factor VIII through specific substitutions in the A1 domain (such as positions 50, 152, and others). These parameter changes at the molecular level alter the protein's properties to reduce immunogenicity while preserving clotting activity, thereby resolving the contradiction between improving clotting function and preventing inhibitor formation.
2Productivity
If high doses of rAAV vectors are used for gene therapy, then FVIII expression is improved, but adverse immune responses occur
Solution Approach 1:
The patent modifies the FVIII protein parameters through amino acid substitutions to enhance its secretion efficiency and stability. This allows achieving adequate FVIII expression levels with lower viral vector doses, thereby reducing the risk of adverse immune responses while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent performs preliminary modification of the FVIII amino acid sequence before gene therapy administration. By pre-engineering the factor VIII protein with improved secretion and stability properties, the therapy can achieve better expression with reduced vector doses, preventing adverse immune responses before they occur.
3Productivity
If amino acid substitutions are made in A1 domain, then secretion ability is improved, but protein structure may be affected
Solution Approach 1:
The patent applies local quality changes by making specific amino acid substitutions at particular positions within the A1 domain rather than throughout the entire protein. This localized modification approach improves secretion ability while minimizing disruption to the overall protein structure and function, as the changes are confined to specific regions that tolerate or benefit from the substitutions.
Data Source
AI summary
The present invention relates to an engineered human factor VIII polypeptide, which includes at least two substituted amino acids in A1 domain of hFVIII. In some embodiments, the substituted amino acids comprise L50V and L152P. In some embodiments, the substituted amino acids further comprise one or more of amino acid substitutions selected from the group consisting of D20S, G22L, I61T, D115E, F129I, G132D, Q139E, and L159F. The present invention also relates to engineered hFVIII polypeptide encoding nucleic acid fragment, an expression vector or a rAAV vector contains such nucleic acid fragment, and a method of using engineered hFVIII polypeptide to treat hemophilia A patients.